5 Topic Commentaries

Cardiometabolic disorders vary by HIV status

• 

  Hugh Auchincloss, MD

  Infectious Diseases

  •

  National Institutes of Health

  “The REPRIEVE study reflects the evolution of HIV science, and progress from focusing mostly on approaches to treat and control the virus to finding ways to improve the overall health of people living with HIV.” “These new data suggest that a common cholesterol-lowering medicine could substantially improve cardiovascular outcomes in people with HIV.”

  Source
• 

  Gary H. Gibbons, MD

  Cardiology

  •

  National Institutes of Health

  “These latest findings represent the culmination of an unprecedented eight-year effort to generate evidence that can help clinicians better support the unique cardiovascular health needs of people living with HIV.” “REPRIEVE is important because there are limited existing interventions to help prevent adverse cardiovascular outcomes in this population.”

  Source
• 

  Matthew J. Feinstein, MD, MS

  Cardiology

  •

  Northwestern University Feinberg School of Medicine

  “The actual risk of heart attack for people with HIV was roughly 50 percent higher than predicted by the risk calculator many physicians use for the general population,”

  Source
• 

  Wendy Post, MD, MS

  Cardiology

  •

  Johns Hopkins University School of Medicine

  “Living with HIV with detectable virus was linked to a larger effect on QT interval variation than any other cardiovascular disease risk factor included in the study, except for diabetes,”

  Source
• 

  Daniel R. Kuritzkes, MD

  Infectious Diseases

  •

  Harvard Medical School and Brigham and Women’s Hospital

  “People living with HIV often have elevated markers of inflammation,” Kuritzkes said. “This chronic immune activation can predispose people to long-term complications, including cardiovascular illness.”

  Source